基于PSMA的放射性配体治疗在激素敏感性前列腺癌中的作用
本综述系统检索PubMed/MEDLINE/EMBASE及clinicaltrials.gov数据库,评估基于PSMA的放射性配体治疗在激素敏感性前列腺癌中的角色。检索获得140条结果,筛选后纳入25篇论文,显示早期RLT在HSPC中具有潜力,并有多个正在进行的临床试验。
要点
- 系统检索获得140条结果,最终纳入25篇论文评估PSMA RLT在HSPC中的潜力。
- 早期使用PSMA RLT在HSPC从新辅助到生化复发(BCR)阶段均具有显著潜力。
- 早期阶段肿瘤负荷较低、更常见单纯淋巴结受累及器官储备较高,可能提高疗效并允许联合治疗。
核心结论
- 早期使用基于PSMA的放射性配体治疗在激素敏感性前列腺癌患者中从新辅助到生化复发阶段均具有显著潜力。
研究设计与样本
- 系统文献综述,检索PubMed/MEDLINE/EMBASE及clinicaltrials.gov数据库中评估PSMA RLT在HSPC中作用的研究和方案。
主要发现
- 系统文献检索获得140条结果。
- 筛选标题和摘要并应用纳入与排除标准后,最终纳入25篇论文显示早期RLT在HSPC中的潜力,并有多个正在进行的临床试验。
- 在这些阶段,肿瘤负荷较低、更常见单纯淋巴结受累及器官储备较高可能提高治疗疗效并允许治疗联合,同时保持较低的毒性特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Conventional systemic therapies are valuable options in prostate cancer (PCa); however, such treatments can determine adverse events and toxicity. The observed improvement in overall survival, coupled with PSA reduction and a favorable safety profile in the post-taxane castration-resistant PCa (CRPC) setting has prompted the consideration of PSMA-based radioligand therapy (RLT) earlier in the treatment sequence. In this review, we will describe the literature and ongoing clinical trials regarding the use of PSMA-based RLT in hormone-sensitive PCa (HSPC) including the neoadjuvant, de-novo/synchronous metastatic, adjuvant, and early BCR settings. METHODS: We performed a systematic literature search on the PubMed/MEDLINE/EMBASE and clinicaltrials.gov databases for studies and protocols assessing the role of PSMA-based RLT in HSPC. RESULTS: The literature search yielded 140 results. After screening titles and abstracts and applying inclusion and exclusion criteria, we selected 25 papers showing the potentialities of earlier RLT in HSPC, with several ongoing trials. CONCLUSION: Early use of PSMA-based RLT holds significant potential in HSPC patients from the neoadjuvant to the BCR setting. In these stages, the lower tumor burden, more frequent exclusive nodal involvement, and higher organ reserve may improve treatment efficacy and allow for treatment combinations while maintaining a less toxic profile.
引用
- Laudicella R, Bauckneht M, Burger IA, et al. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 39934300. doi:10.1007/s00259-025-07083-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。